Cumberland Pharmaceuticals to Announce Q1 2024 Results

Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a company specializing in pharmaceuticals, announced that it will release its financial results for the first quarter of 2024 and provide a company update on May 7, 2024, after the market closes. On the same day, at 4:30 p.m. Eastern Time, a conference call will be held to discuss these results. Participants can register for the call and will receive a dial-in number and PIN, or they can opt for a "Call Me" option, where the system will automatically dial them at the beginning of the conference. A replay of the call will be available for one year on Cumberland's website.

Cumberland Pharmaceuticals focuses on developing, acquiring, and commercializing unique products that enhance patient care across various medical fields, including hospital acute care, gastroenterology, and oncology. The company's portfolio of FDA-approved products includes:

1. Acetadote® (acetylcysteine) injection - Used for treating acetaminophen poisoning.
2. Caldolor® (ibuprofen) injection - Administered to manage pain and fever.
3. Kristalose® (lactulose) for oral solution - A prescription laxative for treating constipation.
4. Omeclamox®-Pak - A combination of omeprazole, clarithromycin, and amoxicillin to treat Helicobacter pylori infections and related duodenal ulcer disease.
5. Sancuso® (granisetron) transdermal system - Prevents nausea and vomiting in patients undergoing certain chemotherapy treatments.
6. Vaprisol® (conivaptan) injection - Used to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia.
7. Vibativ® (telavancin) injection - Treats serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.

Cumberland Pharmaceuticals is also conducting Phase II clinical trials to evaluate its ifetroban product candidate. These trials include studies on patients with cardiomyopathy associated with Duchenne Muscular Dystrophy and Systemic Sclerosis. Recently, the company earned FDA clearance to advance directly to a Phase II study for patients with Idiopathic Pulmonary Fibrosis, a common form of progressive fibrosing interstitial lung disease.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!